Piper Sandler Upgrades Envista Holdings to Overweight, Raises Price Target to $46
Piper Sandler analyst Jason Bednar upgrades Envista Holdings (NYSE:NVST) from Neutral to Overweight and raises the price target from $40 to $46.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Morgan Stanley Maintains Overweight on Envista Holdings, Lowers Price Target to $49
Morgan Stanley analyst Drew Ranieri maintains Envista Holdings (NYSE:NVST) with a Overweight and lowers the price target from $53 to $49.
4 Analysts Have This to Say About Envista Holdings
Analysts have provided the following ratings for Envista Holdings (NYSE:NVST) within the last quarter:
Morgan Stanley Maintains Overweight on Envista Holdings, Lowers Price Target to $53
Morgan Stanley analyst Drew Ranieri maintains Envista Holdings (NYSE:NVST) with a Overweight and lowers the price target from $56 to $53.
Analyst Ratings for Envista Holdings
Within the last quarter, Envista Holdings (NYSE:NVST) has observed the following analyst ratings:
Stifel Maintains Buy on Envista Holdings, Lowers Price Target to $50
Stifel analyst Jonathan Bock maintains Envista Holdings (NYSE:NVST) with a Buy and lowers the price target from $55 to $50.
Envista Holdings’s Return On Capital Employed Overview
Pulled from Benzinga Pro data, Envista Holdings (NYSE:NVST) posted Q1 earnings of $74.90 million, an increase from Q4 of 12.7%. Sales dropped to $631.40 million, a 3.13% decrease between quarters.
Envista To Acquire Osteogenics Biomedical Business; Terms Not Disclosed
ENVISTA TO ACQUIRE OSTEOGENICS BIOMEDICAL BUSINESS
BREA, Calif., May 17, 2022 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced it has entered into a
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.